Lissner D - Search Results

1

TNF hampers intestinal tissue repair in colitis by restricting IL-22 bioavailability.

Ninnemann J, Winsauer C, Bondareva M, Kühl AA, Lozza L, Durek P, Lissner D, Siegmund B, Kaufmann SHE, Mashreghi MF, Nedospasov SA, Kruglov AA. Ninnemann J, et al. Among authors: lissner d. Mucosal Immunol. 2022 Apr;15(4):698-716. doi: 10.1038/s41385-022-00506-x. Epub 2022 Apr 5. Mucosal Immunol. 2022. PMID: 35383266 Free PMC article.

2

The multifaceted role of the inflammasome in inflammatory bowel diseases.

Lissner D, Siegmund B. Lissner D, et al. ScientificWorldJournal. 2011 Jul 28;11:1536-47. doi: 10.1100/tsw.2011.139. ScientificWorldJournal. 2011. PMID: 21805022 Free PMC article. Review.

3

Ulcerative colitis: current and future treatment strategies.

Lissner D, Siegmund B. Lissner D, et al. Dig Dis. 2013;31(1):91-4. doi: 10.1159/000347194. Epub 2013 Jun 17. Dig Dis. 2013. PMID: 23797129 Review.

4

Monocyte and M1 Macrophage-induced Barrier Defect Contributes to Chronic Intestinal Inflammation in IBD.

Lissner D, Schumann M, Batra A, Kredel LI, Kühl AA, Erben U, May C, Schulzke JD, Siegmund B. Lissner D, et al. Inflamm Bowel Dis. 2015 Jun;21(6):1297-305. doi: 10.1097/MIB.0000000000000384. Inflamm Bowel Dis. 2015. PMID: 25901973 Free PMC article.

5

Are Immunosuppressants Becoming Obsolete?

Lissner D, Siegmund B. Lissner D, et al. Dig Dis. 2016;34 Suppl 1:56-60. doi: 10.1159/000447376. Epub 2016 Aug 22. Dig Dis. 2016. PMID: 27548499 Review.

6

Pulmonary Manifestation of Crohn's Disease Developed Under Treatment With Vedolizumab.

Lissner D, Glauben R, Allers K, Sonnenberg E, Loddenkemper C, Schneider T, Siegmund B. Lissner D, et al. Am J Gastroenterol. 2018 Jan;113(1):146-148. doi: 10.1038/ajg.2017.395. Am J Gastroenterol. 2018. PMID: 29311733 No abstract available.

7

[Inflammatory bowel disease: cardinal signs and their diagnostics].

Lissner D, Sonnenberg E, Siegmund B. Lissner D, et al. Dtsch Med Wochenschr. 2018 Jul;113(13):937-944. doi: 10.1055/a-0612-3564. Epub 2018 Jul 4. Dtsch Med Wochenschr. 2018. PMID: 29972837 Review. German.

8

[Cancer Surveillance in Inflammatory Bowel Diseases].

Lissner D, Siegmund B. Lissner D, et al. Dtsch Med Wochenschr. 2019 Jun;144(11):753-756. doi: 10.1055/a-0649-5491. Epub 2019 Jun 4. Dtsch Med Wochenschr. 2019. PMID: 31163475 Review. German.

9

Level of Tumor Necrosis Factor Production by Stimulated Blood Mononuclear Cells Can Be Used to Predict Response of Patients With Inflammatory Bowel Diseases to Infliximab.

Jessen B, Rodriguez-Sillke Y, Sonnenberg E, Schumann M, Kruglov A, Freise I, Schmidt F, Maul J, Kühl AA, Glauben R, Lissner D, Siegmund B. Jessen B, et al. Among authors: lissner d. Clin Gastroenterol Hepatol. 2021 Apr;19(4):721-731.e1. doi: 10.1016/j.cgh.2020.03.066. Epub 2020 Apr 6. Clin Gastroenterol Hepatol. 2021. PMID: 32272247

10

Combination of Vedolizumab With Tacrolimus Is More Efficient Than Vedolizumab Alone in the Treatment of Experimental Colitis.

Manzini R, Schwarzfischer M, Atrott K, Laimbacher A, Lang S, Wawrzyniak M, Rickenbacher A, Turina M, Hruz P, Lissner D, Siegmund B, Rogler G, Scharl M, Spalinger MR. Manzini R, et al. Among authors: lissner d. Inflamm Bowel Dis. 2021 Nov 15;27(12):1986-1998. doi: 10.1093/ibd/izab063. Inflamm Bowel Dis. 2021. PMID: 33847343

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

33 results

Search Page